###begin article-title 0
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5</italic>
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6</italic>
###xml 36 43 36 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1</italic>
###xml 45 53 45 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 520 523 520 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(*3</italic>
###xml 534 536 534 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*4</italic>
###xml 571 573 571 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*2</italic>
###xml 622 624 622 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*2</italic>
###xml 106 114 <span type="species:ncbi:9606">patients</span>
###xml 148 156 <span type="species:ncbi:9606">patients</span>
###xml 647 655 <span type="species:ncbi:9606">patients</span>
Tamoxifen therapy reduces the risk of recurrence and prolongs the survival of oestrogen-receptor-positive patients with breast cancer. Even if most patients benefit from tamoxifen, many breast tumours either fail to respond or become resistant. Because tamoxifen is extensively metabolised by polymorphic enzymes, one proposed mechanism underlying the resistance is altered metabolism. In the present study we investigated the prognostic and/or predictive value of functional polymorphisms in cytochrome P450 3A5 CYP3A5 (*3), CYP2D6 (*4), sulphotransferase 1A1 (SULT1A1; *2) and UDP-glucuronosyltransferase 2B15 (UGT2B15; *2) in tamoxifen-treated patients with breast cancer.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 45 53 <span type="species:ncbi:9606">patients</span>
In all, 677 tamoxifen-treated postmenopausal patients with breast cancer, of whom 238 were randomised to either 2 or 5 years of tamoxifen, were genotyped by using PCR with restriction fragment length polymorphism or PCR with denaturing high-performance liquid chromatography.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 141 149 141 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4</italic>
###xml 155 161 155 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5</italic>
###xml 163 171 163 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 175 183 175 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 266 272 266 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5</italic>
###xml 301 304 301 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*3 </italic>
###xml 520 522 520 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 676 684 676 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*3</italic>
###xml 740 742 740 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 838 844 838 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6</italic>
###xml 846 854 846 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 857 864 857 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15</italic>
###xml 935 944 935 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*3 </italic>
###xml 1029 1031 1029 1031 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1081 1087 1081 1087 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6</italic>
###xml 1089 1097 1089 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 1101 1108 1101 1108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15</italic>
###xml 117 125 <span type="species:ncbi:9606">patients</span>
###xml 696 704 <span type="species:ncbi:9606">patients</span>
The prognostic evaluation performed in the total population revealed a significantly better disease-free survival in patients homozygous for CYP2D6*4. For CYP3A5, SULT1A1 and UGT2B15 no prognostic significance was observed. In the randomised group we found that for CYP3A5, homozygous carriers of the *3 allele tended to have an increased risk of recurrence when treated for 2 years with tamoxifen, although this was not statistically significant (hazard ratio (HR) = 2.84, 95% confidence interval (CI) = 0.68 to 11.99, P = 0.15). In the group randomised to 5 years' tamoxifen the survival pattern shifted towards a significantly improved recurrence-free survival (RFS) among CYP3A5*3-homozygous patients (HR = 0.20, 95% CI = 0.07 to 0.55, P = 0.002). No reliable differences could be seen between treatment duration and the genotypes of CYP2D6, SULT1A1 or UGT2B15. The significantly improved RFS with prolonged tamoxifen treatment in CYP3A5*3 homozygotes was also seen in a multivariate Cox model (HR = 0.13, CI = 0.02 to 0.86, P = 0.03), whereas no differences could be seen for CYP2D6, SULT1A1 and UGT2B15.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 255 262 255 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5 </italic>
The metabolism of tamoxifen is complex and the mechanisms responsible for the resistance are unlikely to be explained by a single polymorphism; instead it is a combination of several mechanisms. However, the present data suggest that genetic variation in CYP3A5 may predict response to tamoxifen therapy.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 250 251 250 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 793 794 793 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 795 796 795 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 955 956 955 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 957 958 957 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 55 63 <span type="species:ncbi:9606">patients</span>
###xml 218 223 <span type="species:ncbi:9606">women</span>
###xml 287 295 <span type="species:ncbi:9606">patients</span>
Tamoxifen is widely used as an endocrine treatment for patients with oestrogen-receptor (ER)-positive breast cancer. Five years of adjuvant tamoxifen therapy reduces the risk of recurrence and prolongs the survival of women with ER-positive tumours [1]. Nevertheless, in a proportion of patients, tumours are resistant to tamoxifen, or become so, with a subsequent relapse in the disease. The mechanisms underlying the resistance are not fully understood. Because there is convincing evidence that tamoxifen is converted to anti-oestrogenic metabolites that are more potent than the mother substance, one hypothesis is that altered metabolism might contribute to inter-individual variability in serum concentrations, which in turn may influence the action on ER and the response to treatment [2-4]. Some studies have demonstrated considerable inter-individual variation in concentrations of tamoxifen metabolites both in plasma and locally in the breast [5,6].
###end p 11
###begin p 12
###xml 60 61 60 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 93 94 93 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 297 298 297 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 299 300 299 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 344 353 344 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 531 532 531 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 533 534 533 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 537 538 537 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 599 600 599 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 601 602 601 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 603 604 603 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 605 606 605 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 733 734 733 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 842 844 842 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 845 847 845 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 902 908 902 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans </italic>
###xml 914 918 914 918 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis </italic>
###xml 1039 1041 1039 1041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1042 1044 1042 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1047 1050 1047 1050 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cis</italic>
###xml 1140 1145 1140 1145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
###xml 1236 1238 1236 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1267 1269 1267 1269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1333 1338 1333 1338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
###xml 1386 1389 1386 1389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 1548 1550 1548 1550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1169 1177 <span type="species:ncbi:9606">patients</span>
Several primary metabolites have been identified, including N-desmethyl-tamoxifen, 4-hydroxy-N-desmethyl-tamoxifen (endoxifen) and 4-hydroxy-tamoxifen. Whereas tamoxifen has a relatively low affinity for ER, the metabolite 4-hydroxy-tamoxifen binds with an affinity similar to that of oestradiol [7,8]. It has also been demonstrated by studies in vitro that endoxifen exhibits a cpotency similar to that of 4-hydroxy-tamoxifen with regard to ER binding affinity, suppression of oestrogen-dependent cell growth and gene expression [2-4]. N-desmethyl-tamoxifen, in contrast, is a weak anti-oestrogen [2,3,7-9]. Previous studies have shown that cytochrome P450 3A4 and cytochrome P450 3A5 (CYP3A4 and CYP3A5) are the major catalysts of N-demethylation, whereas the 4-hydroxylation is predominantly supported by the cytochrome P450 2D6 (CYP2D6) [10-12]. The 4-hydroxy-tamoxifen is in equilibrium between a trans and a cis isoform, resulting in a proposed shift in property from a potent anti-oestrogen towards a significantly less potent one [13-15]. Cis-4-hydroxy-tamoxifen has in addition been reported to exist at higher concentrations than trans-4-hydroxy-tamoxifen in patients with breast cancer with acquired resistance to tamoxifen [16]. Nishiyama and colleagues [17] suggested a geometrical selectivity in both the sulphation of trans-4-hydroxy-tamoxifen and the glucuronidation of cis-4-hydroxy-tamoxifen, and that these reactions were catalysed by sulphotransferase 1A1 (SULT1A1) and UDP-glucuronosyltransferase 2B15 (UGT2B15), respectively [17].
###end p 12
###begin p 13
###xml 161 168 161 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5 </italic>
###xml 223 231 223 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*3</italic>
###xml 345 347 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 348 350 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 356 363 356 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 404 412 404 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4</italic>
###xml 502 509 500 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 567 569 565 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 619 627 617 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 686 696 682 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*2 </italic>
###xml 783 785 779 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 842 850 838 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 895 897 891 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 947 956 943 952 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15*1</italic>
###xml 971 980 967 976 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15*2</italic>
###xml 1091 1093 1087 1089 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1160 1167 1156 1163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 1171 1179 1167 1175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 1347 1356 1343 1352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 1398 1407 1394 1403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*1</italic>
###xml 1452 1454 1448 1450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1635 1642 1631 1638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5 </italic>
###xml 1643 1652 1639 1648 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*1 </italic>
###xml 1656 1658 1652 1654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*3</italic>
###xml 1661 1668 1657 1664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 1669 1678 1665 1674 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*1 </italic>
###xml 1682 1684 1678 1680 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*4</italic>
###xml 1687 1695 1683 1691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 1696 1706 1692 1702 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*1 </italic>
###xml 1711 1712 1707 1708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 1718 1726 1714 1722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 1727 1737 1723 1733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15*1 </italic>
###xml 1741 1743 1737 1739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*2</italic>
###xml 2023 2032 2019 2028 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*1 </italic>
###xml 2036 2044 2032 2040 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*1</italic>
###xml 2124 2134 2120 2130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*2 </italic>
###xml 2138 2147 2134 2143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15*1</italic>
###xml 1201 1209 <span type="species:ncbi:9606">patients</span>
###xml 1374 1382 <span type="species:ncbi:9606">patients</span>
###xml 1795 1803 <span type="species:ncbi:9606">patients</span>
Polymorphisms affecting enzyme activity have been found in CYP3A5, CYP2D6, SULT1A1 and UGT2B15. The most frequent and functionally important polymorphism in the CYP3A5 gene consists of an A6986G transition within intron 3 (CYP3A5*3). This polymorphism creates an alternative splice site resulting in a frame shift and truncation of the protein [18-20]. In CYP2D6 the most common non-functional allele is CYP2D6*4. This polymorphism generates a G-->A transition at the first nucleotide of exon 4 in the CYP2D6 gene, leading to a truncated non-functional gene product [21]. Further, the most frequent polymorphism in the SULT1A1 gene is a G-->A transition at nucleotide 638, defining the SULT1A1*2 allele, which is correlated with a diminished capacity to sulphate SULT1A1 substrates [22]. Several polymorphisms have also been found within the UGT2B15 gene although only two in the coding region [23]. One causes an amino acid shift from aspartate (UGT2B15*1) to tyrosine (UGT2B15*2) at position 85 of the UGT2B15 protein, a shift that has been associated with an increase in enzyme activity [24]. In a previous study we investigated functional polymorphisms in CYP2D6 and SULT1A1 in 226 postmenopausal patients with breast cancer randomised to treatment with or without tamoxifen. We found a benefit of tamoxifen in carriers of the inactive allele CYP2D6*4 and a tendency in patients homozygous for SULT1A1*1, when compared with the control population [25]. In the present study a new cohort was investigated that was both larger and included additional polymorphic enzymes involved in the metabolism of tamoxifen. The polymorphisms of CYP3A5 (CYP3A5*1 and *3), CYP2D6 (CYP2D6*1 and *4), SULT1A1 (SULT1A1*1 and *2) and UGT2B15 (UGT2B15*1 and *2) were examined in tamoxifen-treated postmenopausal patients with breast cancer, to discern whether the genotypes correlated with clinical/pathological factors and/or to the benefit of tamoxifen. We proposed that the alleles contributing to the bioactivation of tamoxifen (namely CYP3A5*1 and CYP2D6*1) as well as the alleles delaying the elimination of active metabolites (namely SULT1A1*2 and UGT2B15*1) would be favourable.
###end p 13
###begin title 14
Materials and methods
###end title 14
###begin title 15
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 15
###begin p 16
###xml 366 367 366 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 750 752 750 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
###xml 373 381 <span type="species:ncbi:9606">patients</span>
###xml 476 484 <span type="species:ncbi:9606">patients</span>
###xml 552 560 <span type="species:ncbi:9606">Patients</span>
###xml 684 692 <span type="species:ncbi:9606">patients</span>
###xml 763 771 <span type="species:ncbi:9606">patients</span>
###xml 804 812 <span type="species:ncbi:9606">patients</span>
We analysed frozen tumour tissues from 677 postmenopausal patients with stage II and III breast cancer. They were diagnosed between 1986 and 1997 in the South East Health Care Region of Sweden and were between 50 and 96 years old, with a mean age of 69 years at the time of diagnosis. Information on tumour size, lymph-node status and tumour stage is shown in Table 1. All patients were ER-positive and had received adjuvant postoperative tamoxifen therapy. A subgroup of 238 patients was randomised to either 2 or 5 years of treatment with tamoxifen. Patients diagnosed before 1994 received a daily dosage of 40 mg tamoxifen for 2 or 5 years. After 1 January 1994 all postmenopausal patients received 20 mg for 5 years. In the non-randomised group (n = 439) 175 patients were treated with 40 mg and 264 patients with 20 mg of tamoxifen. The mean follow-up time in the total population was 7.3 years (range 0.04 to 17.9, median 7.08). For the randomised group the mean follow-up time in the 2-year arm was 9.8 years (range 2.3 to 17.7, median 9.8) and in the 5-year arm 10.7 years (range 2.1 to 17.9, median 10.7). The study was approved by the local ethical committee in Linkoping, Sweden (register number 03-608).
###end p 16
###begin title 17
DNA isolation and PCR
###end title 17
###begin p 18
Fresh frozen breast tumour tissues (about 30 mg) were homogenised with a microdismembrator (B Braun, Melsungen, Germany), and genomic DNA was then isolated with the SV Genomic DNA Purification System (Promega Corporation, Madison, WI, USA). The DNA content was determined by spectrophotometry, and purified DNA was stored at -20degreesC before use.
###end p 18
###begin p 19
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5</italic>
###xml 12 18 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6</italic>
###xml 20 28 20 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 32 40 32 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 149 156 149 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 160 168 160 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 275 282 275 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5 </italic>
###xml 286 294 286 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 572 573 571 572 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 601 605 600 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
###xml 963 969 934 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6</italic>
###xml 971 978 942 949 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1</italic>
###xml 995 1001 960 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5</italic>
###xml 1003 1010 968 975 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15</italic>
The CYP3A5, CYP2D6, SULT1A1 and UGT2B15 genes were amplified by PCR in separate reactions with 50 ng of DNA. The primer sequences used in the PCR of CYP2D6 and SULT1A1 were adopted from Hanioka and colleagues [21] and Coughtrie and colleagues [26], respectively, whereas the CYP3A5 and UGT2B15 genes were amplified with forward (5'-ACCACCCAGCTTAACGAATG-3' and 5'-AGAGCTTGTTCAGAGGGGTCATGAG-3') and reverse (5'-AGCACAGGGAGTTGACCTTC-3' and 5'-AAATTCTCGATAGATGGATATATGG-3') primers, respectively. The following PCR reagents were added to a reaction volume of 20 mul: 2 mM MgCl2, 0.2 mM dNTPs, 0.5 unit of Taq DNA polymerase, and 1 muM each of forward and reverse primer in 1 x PCR buffer. The amplification was performed in a PTC-200 Peltier Thermal Cycler DNA Engine (MJ Researchtrade mark Inc, Waltham, MA, USA). An initial denaturation at 94degreesC for 3 minutes was followed by 38 to 40 cycles of 30 seconds at 94degreesC, 30 seconds of annealing at 63degreesC (CYP2D6, SULT1A1) or 64degreesC (CYP3A5, UGT2B15), and 40 seconds of extension at 72degreesC. An extension period of 5 minutes followed the final cycle. Fragments were then resolved by electrophoresis on a 2% (w/v) agarose gel containing 1 x TBE (89 mM Tris, 89 mM boric acid, 2 mM EDTA, pH 8.4) buffer and ethidium bromide (0.5 mug/mul). The gel was finally processed in an ultraviolet detector (Spectromics Corporation, New York, NY, USA).
###end p 19
###begin title 20
Restriction fragment length polymorphism
###end title 20
###begin p 21
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 15 23 15 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 85 88 85 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mva</italic>
###xml 135 144 135 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 154 161 154 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 193 202 193 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 291 301 291 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*1 </italic>
###xml 338 341 338 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hae</italic>
###xml 371 381 371 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*2 </italic>
###xml 391 394 391 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mva</italic>
###xml 453 455 452 454 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 520 527 519 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 587 595 580 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 662 665 655 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hae</italic>
###xml 912 918 <span type="species:ncbi:9913">bovine</span>
The CYP2D6 and SULT1A1 polymorphisms were detected by using restriction enzymes. The MvaI restriction enzyme distinguishes between the CYP2D6*4 and other CYP2D6 alleles. The polymorphic allele CYP2D6*4 lacks the restriction site and is thereby retained as one fragment. The wild-type allele SULT1A1*1 has a restriction site recognised by HaeII but the polymorphic allele SULT1A1*2 does not. MvaI (10 units; Fermentas, Stockholm, Sweden) and 1.5 mul of R+ buffer (supplied by the manufacturer) were added to each tube of CYP2D6 PCR products and incubated at 37degreesC for 2.5 hours. The SULT1A1 PCR products were incubated with 5 units of the restriction enzyme HaeII (New England BioLabs, Beverly, MA, USA) in a 20 mul reaction mixture containing 1 x NE buffer (50 mM potassium acetate, 20 mM Tris-acetate, 10 mM magnesium acetate, 1 mM dithiothreitol, pH 7.9; New England BioLabs) supplemented with 100 mug/ml bovine serum albumin. After digestion, fragments were resolved by electrophoresis on a 3% (w/v) agarose gel containing 1 x TBE buffer and ethidium bromide (0.5 mug/mul). The gel was finally processed in an ultraviolet detector. To confirm the genotypes obtained with the restriction fragment length polymorphism method, 20 randomly selected samples were DNA sequenced and no differences in genotype were detected between the methods.
###end p 21
###begin title 22
###xml 17 21 17 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
Transgenomic Wave(R) - nucleic acid fragment analysis system (denaturing high-performance liquid chromatography)
###end title 22
###begin p 23
###xml 21 25 21 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 123 131 121 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*1</italic>
###xml 133 136 131 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*3 </italic>
###xml 140 149 138 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15*1</italic>
###xml 151 154 149 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*2 </italic>
###xml 301 305 299 301 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 623 631 607 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 635 642 619 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5 </italic>
The Transgenomic Wave(R) system is based on the principle of liquid chromatography and was used to separate and detect the CYP3A5*1, *3 and UGT2B15*1, *2 alleles amplified by PCR. In this system, DNA fragments are carried by a gradient buffer (with a 2% increase in buffer per minute) through a DNASep(R) Cartridge under isothermal (58degreesC and 55.6degreesC, respectively) conditions, with subsequent detection by absorbance at 260 nm. The buffers used in the system consists of 0.1 M triethylammonium acetate (TEAA) and 25% (v/v) acetonitrile and 0.1 M TEAA (gradient buffer). To estimate the retention pattern for the UGT2B15 and CYP3A5 alleles, a few samples were DNA sequenced by a Thermo Sequenase Kit (Amersham Pharmacia Biotech, Uppsala, Sweden) and used as controls for each genotype.
###end p 23
###begin title 24
Statistical analyses
###end title 24
###begin p 25
###xml 91 93 80 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 1242 1244 1231 1233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 253 258 <span type="species:ncbi:9606">woman</span>
###xml 281 287 <span type="species:ncbi:9606">person</span>
###xml 572 580 <span type="species:ncbi:9606">patients</span>
SPSS Advanced Modelstrade mark 12.0 software was used for the statistical analyses. The chi2 test was used to show differences in the distribution of genotypes according to lymph-node status, tumour size and tumour stage. In the survival analyses, each woman's contribution to the person-years at risk began from the date of initial surgery to 1 January 2004, to the date of local or distant recurrences, whichever was earlier. The survival curves of recurrences were estimated with the Kaplan-Meier method, and the significance of differences between survival rates, for patients with different genotypes and endocrine treatment, was assessed by log-rank test. A univariate Cox proportional-hazard model was used for the estimation of the hazard ratio (HR) comparing genotype for each treatment group. Further, we performed a multivariate Cox model to adjust for the different tumour characteristics between the genotypes. We also tested whether the calculated hazard ratios were significantly different between treatment groups by using an interaction test according to the Cox model (treatment (0/1), genotype (0/1) and treatment x genotype (0/1)). Differences between groups were judged significant at confidence levels greater than 95% (P < 0.05).
###end p 25
###begin title 26
Results
###end title 26
###begin p 27
###xml 54 62 54 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*3</italic>
###xml 71 79 71 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*1</italic>
###xml 88 97 88 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*1</italic>
###xml 109 118 109 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15*2</italic>
###xml 197 205 197 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*3</italic>
###xml 207 216 207 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 220 229 220 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*2</italic>
###xml 366 367 366 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 273 281 <span type="species:ncbi:9606">patients</span>
The frequencies of the most common alleles were 0.92 (CYP3A5*3), 0.82 (CYP2D6*1), 0.61 (SULT1A1*1) and 0.52 (UGT2B15*2). Homozygous genotypes representing blocked or diminished enzymatic activity, CYP3A5*3, CYP2D6*4 and SULT1A1*2, were seen in 84.9%, 5.0% and 15.2% of the patients, respectively. Information on genotype and tumour characteristics is shown in Table 1. There was no significant difference in the distribution of tumour characteristics according to genotype.
###end p 27
###begin p 28
###xml 225 234 225 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 336 339 336 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*1 </italic>
###xml 347 349 347 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 360 362 360 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 392 393 392 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 501 508 501 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 524 526 524 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 540 546 540 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5</italic>
###xml 548 556 548 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 560 567 560 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15</italic>
###xml 197 205 <span type="species:ncbi:9606">patients</span>
###xml 283 291 <span type="species:ncbi:9606">patients</span>
To evaluate whether the genotypes were of prognostic importance in terms of recurrence-free survival (RFS), we calculated each polymorphism separately. The Kaplan-Meier estimates demonstrated that patients homozygous for the CYP2D6*4 allele had a significantly better prognosis than patients who were homozygous or heterozygous for the *1 allele (P = 0.05 and P = 0.04, respectively) (Figure 1). In a multivariate Cox analysis including tumour stage, tumour size and lymph-node status, the result for CYP2D6 was less clear (P = 0.055). For CYP3A5, SULT1A1 and UGT2B15, no significant difference was seen regarding prognosis (data not shown).
###end p 28
###begin p 29
###xml 70 72 70 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 201 207 201 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5</italic>
###xml 209 215 209 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6</italic>
###xml 217 225 217 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 229 237 229 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 29 37 <span type="species:ncbi:9606">patients</span>
###xml 448 456 <span type="species:ncbi:9606">patients</span>
Among the 677 postmenopausal patients with breast cancer, a subgroup (n = 238) was randomised to either 2 or 5 years of adjuvant tamoxifen. In the randomised group we examined whether the genotypes of CYP3A5, CYP2D6, SULT1A1 and UGT2B15 could influence the benefit of tamoxifen. When calculating the predictive value, cases with less than 2 years of follow-up time were excluded. In the statistical analyses we combined homozygous and heterozygous patients to equalise the different groups when the number of either homozygous genotype was low. Initially, we compared the RFS by genotype and by randomisation with log-rank test. Next, we estimated the HR for each genotype in the two treatment groups by using a univariate Cox proportional hazard model. Finally, we performed a multivariate Cox model adjusted for tumour characteristics such as stage, size, lymph-node involvement and tamoxifen duration. The predictive value of each genotype was further evaluated with an interaction test that compared the estimated HRs.
###end p 29
###begin p 30
###xml 27 28 27 28 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 74 82 74 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 86 93 86 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5 </italic>
###xml 193 203 193 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*1 </italic>
###xml 245 247 245 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 368 376 368 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 396 397 396 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 300 308 <span type="species:ncbi:9606">patients</span>
The HRs presented in Table 2 demonstrate significant associations for the SULT1A1 and CYP3A5 genotypes and RFS. We found an improved RFS with 2 years of tamoxifen in homozygous carriers of the SULT1A1*1 allele (HR = 0.33, 95% CI = 0.12 to 0.96, P = 0.04). However, no such difference was detected in patients randomised to 5 years of tamoxifen. The survival curves of SULT1A1 are shown in Figure 2.
###end p 30
###begin p 31
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5</italic>
###xml 39 42 39 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*3 </italic>
###xml 220 222 220 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 236 237 236 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 374 383 374 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*3 </italic>
###xml 438 440 438 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 455 456 455 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 497 499 497 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 501 503 501 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 612 621 612 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*3 </italic>
###xml 639 641 639 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 656 657 656 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 686 693 686 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 697 704 697 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15</italic>
###xml 760 761 760 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 766 767 766 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 778 779 778 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 834 843 834 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 945 954 945 954 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*1 </italic>
###xml 955 957 955 957 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1154 1163 1154 1163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*3 </italic>
###xml 1289 1291 1289 1291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1333 1339 1333 1339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6</italic>
###xml 1341 1349 1341 1349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 1353 1360 1353 1360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15</italic>
###xml 394 402 <span type="species:ncbi:9606">patients</span>
###xml 794 802 <span type="species:ncbi:9606">patients</span>
###xml 921 929 <span type="species:ncbi:9606">patients</span>
###xml 1130 1138 <span type="species:ncbi:9606">patients</span>
For CYP3A5, homozygous carriers of the *3 allele tended to have an increased risk of recurrence when treated with 2 years of tamoxifen, although this was not statistically significant (HR = 2.84, 95% CI = 0.68 to 11.99, P = 0.15; Table 2 and Figure 3a). In the group randomised to 5 years of tamoxifen the survival pattern shifted towards a significantly improved RFS among CYP3A5*3 homozygous patients (HR = 0.20, 95% CI = 0.07 to 0.55, P = 0.002; Table 2). The survival curve is shown in Figure 3b (P = 0.0005). When comparing HRs the benefit of 5 years of tamoxifen associated with homozygous carriers of the CYP3A5*3 allele persisted (P = 0.003; Table 2). The other genes examined (CYP2D6 and UGT2B15) showed no significant difference by genotype (Figures 4 and 5 and Table 2), even though patients homozygous or heterozygous for CYP2D6*4 had a tendency towards improved benefit of 5 years of tamoxifen compared with patients homozygous for CYP2D6*1 (P = 0.12). Furthermore, when we adjusted for tamoxifen duration, tumour stage, tumour size and lymph-node status and performed an interaction test when significance occurred, patients homozygous for CYP3A5*3 still had a significantly decreased risk of recurrence when treated for 5 years with tamoxifen (HR = 0.13, CI = 0.02 to 0.86, P = 0.03). No differences could be seen for CYP2D6, SULT1A1 and UGT2B15.
###end p 31
###begin title 32
Discussion
###end title 32
###begin p 33
###xml 141 148 141 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 152 160 152 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 295 304 295 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 342 352 342 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*1 </italic>
###xml 360 362 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 916 918 916 918 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 1186 1195 1186 1195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*3 </italic>
###xml 1281 1290 1281 1290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*1 </italic>
###xml 1408 1417 1408 1417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 24 32 <span type="species:ncbi:9606">patients</span>
###xml 260 268 <span type="species:ncbi:9606">patients</span>
###xml 627 635 <span type="species:ncbi:9606">patients</span>
###xml 697 705 <span type="species:ncbi:9606">patients</span>
###xml 946 954 <span type="species:ncbi:9606">patients</span>
###xml 1158 1166 <span type="species:ncbi:9606">patients</span>
###xml 1257 1265 <span type="species:ncbi:9606">patients</span>
###xml 1374 1382 <span type="species:ncbi:9606">patients</span>
###xml 1507 1515 <span type="species:ncbi:9606">patients</span>
In a previous report of patients with breast cancer randomised to treatment with and without tamoxifen we found that genetic polymorphism in CYP2D6 and SULT1A1 may predict the benefit of tamoxifen therapy with a significantly improved disease-free survival in patients that were carriers of the CYP2D6*4 allele and/or were homozygous for the SULT1A1*1 allele [25]. In the present investigation we examined a different and larger cohort, which also included additional polymorphic enzymes that participate in the biotransformation and elimination of tamoxifen. The study design between these investigations differs, because all patients received tamoxifen in the current study. However, of the 677 patients with breast cancer analysed, a subgroup was randomised to either 2 or 5 years of tamoxifen and an attempt was made to calculate the predictive value of the polymorphic enzymes within the randomised population (n = 238). In this population, patients were treated differently 2 years after the start of tamoxifen treatment and we therefore compared RFS for each randomised group and genotype. In the group treated with 5 years of tamoxifen we found that patients homozygous for the CYP3A5*3 variant allele had a significantly improved RFS compared with patients harbouring the CYP3A5*1 allele, and we could also see a weak tendency for a decreased risk of recurrence in patients who were carriers of the CYP2D6*4 variant allele. However, the relevance of this finding is uncertain because the number of patients was limited.
###end p 33
###begin p 34
###xml 163 172 163 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*3 </italic>
###xml 208 217 208 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*1 </italic>
###xml 393 399 393 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6</italic>
###xml 401 409 401 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 413 421 413 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 458 465 458 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 615 624 615 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 688 690 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 733 735 733 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 757 766 757 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 908 910 908 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 954 963 954 963 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 1087 1096 1087 1096 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 135 143 <span type="species:ncbi:9606">patients</span>
###xml 930 938 <span type="species:ncbi:9606">patients</span>
###xml 1135 1143 <span type="species:ncbi:9606">patients</span>
###xml 1195 1202 <span type="species:ncbi:9606">patient</span>
A comparison of the hazard ratios calculated for each treatment group demonstrated that the risk reduction was significantly higher in patients homozygous for the CYP3A5*3 allele than in those harbouring the CYP3A5*1 allele. This was also true when we adjusted for tumour size, tumour stage and lymph-node status. No association between the outcome of tamoxifen treatment and the genotypes of CYP2D6, SULT1A1 and UGT2B15 was found. Even if the assessment of CYP2D6 showed no significant influence in the randomised groups, there was a tendency for an advantage with 5 years of tamoxifen in carriers of at least one CYP2D6*4 allele. This is partly in agreement with our previous findings [25] and with those of Nowell and colleagues [27], who noted that the CYP2D6*4 variant seemed to be associated with a decreased risk of death or recurrence. In contrast, a recent prognostic study by Goetz and colleagues [28] demonstrated that patients homozygous for CYP2D6*4 had both significantly worse relapse-free time and disease-free survival but not overall survival. Because their homozygous CYP2D6*4 genotype constitutes a small number of patients, results should therefore be confirmed in a larger patient population.
###end p 34
###begin p 35
###xml 252 254 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 289 298 289 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*3 </italic>
###xml 430 439 430 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*3 </italic>
###xml 514 523 514 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*3 </italic>
###xml 676 677 676 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 782 784 782 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 835 842 835 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5 </italic>
###xml 1009 1018 1009 1018 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*3 </italic>
###xml 1071 1073 1071 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1124 1133 1124 1133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*1 </italic>
###xml 1216 1223 1216 1223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5 </italic>
###xml 1239 1241 1239 1241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*3</italic>
###xml 1242 1244 1242 1244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*3</italic>
###xml 1427 1429 1427 1429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1430 1432 1430 1432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1656 1658 1656 1658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 213 220 <span type="species:ncbi:9606">patient</span>
###xml 320 327 <span type="species:ncbi:9606">patient</span>
###xml 490 498 <span type="species:ncbi:9606">patients</span>
###xml 898 906 <span type="species:ncbi:9606">patients</span>
Several studies have been performed on the CYP3A5 enzyme and tamoxifen, although results are controversial. The reports have focused mainly on the concentration of metabolites and its association with genotype or patient outcome. Goetz and colleagues [28] attempted to investigate whether CYP3A5*3 polymorphism affected patient outcome. They found no differences in relapse-free time, disease-free survival or overall survival by CYP3A5*3 genotype. Our novel findings of an improved RFS in patients homozygous for CYP3A5*3 was unexpected because this genotype represents an inactive form of the enzyme and should therefore not catalyse the formation of the primary metabolite N-desmethyl-tamoxifen, which is a precursor of the ER-active metabolite endoxifen. Tucker and colleagues [29] recently tested whether genetic polymorphisms in CYP3A5 were associated with altered metabolism of tamoxifen in patients with breast cancer. They found no significant differences in tamoxifen or metabolite concentration by CYP3A5*3 polymorphic status. In contrast, Jin and colleagues [30] suggested that subjects who carried at least one CYP3A5*1 allele had higher plasma concentrations of endoxifen than those lacking functional CYP3A5 alleles (namely *3/*3), although this was not statistically significant. In addition, several authors have proposed that CYP3A5 might be a minor contributor to the overall metabolism of CYP3A substrates [31-33]. There is also a large overlap in substrate specificity between CYP3A4 and CYP3A5, so the contribution of each CYP3A4 and CYP3A5 to total CYP3A activity could thus depend on both the drug and the individual exposed to it [34].
###end p 35
###begin p 36
###xml 17 25 17 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 160 170 160 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*1 </italic>
###xml 231 233 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 311 321 311 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*1 </italic>
###xml 419 421 419 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 448 456 448 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 460 468 460 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 730 740 730 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15*2 </italic>
###xml 744 754 744 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*2 </italic>
###xml 807 815 807 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 860 862 860 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 484 492 <span type="species:ncbi:9606">patients</span>
The influence of SULT1A1 in the current investigation did not reveal any conclusive implication, either in the prognostic nor in the predictive evaluation. The SULT1A1*1 allele was previously investigated by Nowell and colleagues [35] and by our group [25]; both studies indicated that the high-activity allele SULT1A1*1 contributed significantly to tamoxifen response. In a more recent study by Nowell and colleagues [27], genetic polymorphism in SULT1A1 and UGT2B15 was analysed in patients with breast cancer treated with or without tamoxifen. They demonstrated that genetic variation in these phase II enzymes alone or in combination was associated with overall survival and recurrence of disease. Individuals possessing both UGT2B15*2 and SULT1A1*2 alleles had a significantly increased risk of death. SULT1A1 was also investigated by Jin and colleagues [30], who studied whether the mean plasma concentration of tamoxifen and its metabolites was associated with genetic variants of this gene, but no such correlation was found.
###end p 36
###begin p 37
###xml 175 176 175 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 345 346 345 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 347 349 347 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 350 352 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 92 100 <span type="species:ncbi:9606">patients</span>
Co-administration of drugs (such as selective serotonin reuptake inhibitors (SSRI)) used in patients with breast cancer has been shown to inhibit the metabolism of tamoxifen [2,30]. This is an important issue because changes in the concentrations of active metabolites might influence the outcome of therapy; however, results are controversial [2,30,36,37]. The influence from SSRI co-administration in our investigation is likely to be a minor problem because such drugs were rarely used in the current study population.
###end p 37
###begin p 38
###xml 490 496 490 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5</italic>
###xml 498 504 498 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6</italic>
###xml 506 514 506 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 518 526 518 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 638 646 638 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*3</italic>
###xml 648 656 648 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*1</italic>
###xml 658 668 658 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*2 </italic>
###xml 672 682 672 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15*2 </italic>
###xml 783 785 783 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 786 788 786 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 789 791 789 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 792 794 792 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
In the present study, only tumour DNA was available for genotyping and this introduces a risk for misclassification of genotypes because loss of heterozygosity and gene mutations frequently occur at several sites during carcinogenesis. However, breast tumour tissues are a mixture of stromal, inflammatory and malignant cells, and genetic lesions usually affect only a subgroup of tumour cells. Therefore the presence of normal cells and malignant cells without DNA lesions in the locus of CYP3A5, CYP2D6, SULT1A1 and UGT2B15 decreases the risk of genotype misclassification. This is also supported by the fact that allele frequencies of CYP3A5*3, CYP2D6*1, SULT1A1*2 and UGT2B15*2 in the current study population are comparable to those reported by others in Caucasian populations [18,19,26,27].
###end p 38
###begin title 39
Conclusion
###end title 39
###begin p 40
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 418 420 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 483 492 483 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*1</italic>
###xml 494 503 494 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 507 516 507 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*3 </italic>
###xml 594 596 594 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 597 599 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 673 675 673 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1047 1054 1047 1054 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5 </italic>
###xml 97 105 <span type="species:ncbi:9606">patients</span>
###xml 460 468 <span type="species:ncbi:9606">patients</span>
Taken together, the current investigation and earlier published reports [25,27,35] of randomised patients connected with polymorphisms in metabolic enzymes and the outcome of tamoxifen give rise to questions about the hypothesis that genotypes contributing to the biosynthesis of the ER-active metabolites (such as endoxifen and 4-hydroxy-tamoxifen) improve the benefit of tamoxifen. Investigations by Nowell's group [35] and from our laboratory indicate that patients who carry the SULT1A1*1, CYP2D6*4 and CYP3A5*3 alleles, which give less ER-active metabolites, might benefit from tamoxifen [25,27], whereas others have found the opposite, particularly regarding CYP2D6 [28]. However, the metabolism of tamoxifen is complex and the enzymes contributing in this process can also be affected by co-prescribed drugs. The mechanisms responsible for the resistance are therefore unlikely to be explained by a single polymorphism but rather by a combination of several mechanisms. Nevertheless, the present investigation suggests that the genotype of CYP3A5 may contribute to tamoxifen response.
###end p 40
###begin title 41
Abbreviations
###end title 41
###begin p 42
CI = confidence interval; CYP3A4 = cytochrome P450 3A4; CYP3A5 = cytochrome P450 3A5; CYP2D6 = cytochrome P450 2D6; ER = oestrogen receptor; HR = hazard ratio; PCR = polymerase chain reaction; RFS = recurrence-free survival; SSRI = selective serotonin reuptake inhibitors; SULT1A1 = sulphotransferase 1A1; TEAA = triethylammonium acetate; UGT2B15 = UDP-glucuronosyltransferase 2B15.
###end p 42
###begin title 43
Competing interests
###end title 43
###begin p 44
The authors declare that they have no competing interests.
###end p 44
###begin title 45
Authors' contributions
###end title 45
###begin p 46
PW conducted part of the laboratory work, performed the statistical analyses and drafted the manuscript. SE conducted part of the laboratory work. JC conceived the statistical analyses. OS contributed with the coordination of the study and participated in the preparation of the manuscript. BN provided tumour material and clinical data. SW conceived the study and participated in its design and coordination. All authors participated in the preparation of the manuscript and approved the final version.
###end p 46
###begin title 47
Acknowledgements
###end title 47
###begin p 48
We thank Birgitta Holmlund and Lilian Ferraud at the Division of Oncology, Linkoping University Hospital, for technical assistance. This study was supported by grants from the Swedish Cancer and Allergy Society, the Swedish Cancer Society, the Gunnar Nilsson Cancer Foundation and the Percy Falks Cancer Foundation.
###end p 48
###begin article-title 49
Tamoxifen for early breast cancer: an overview of randomised trials
###end article-title 49
###begin article-title 50
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
###end article-title 50
###begin article-title 51
Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen
###end article-title 51
###begin article-title 52
###xml 21 22 21 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen
###end article-title 52
###begin article-title 53
Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours
###end article-title 53
###begin article-title 54
Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial
###end article-title 54
###begin article-title 55
###xml 125 130 <span type="species:ncbi:9606">human</span>
###xml 182 190 <span type="species:ncbi:9606">patients</span>
Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer
###end article-title 55
###begin article-title 56
Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth
###end article-title 56
###begin article-title 57
Structure function relationship of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro
###end article-title 57
###begin article-title 58
###xml 113 118 <span type="species:ncbi:9606">human</span>
Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes
###end article-title 58
###begin article-title 59
###xml 98 103 <span type="species:ncbi:9606">human</span>
Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes
###end article-title 59
###begin article-title 60
###xml 46 51 <span type="species:ncbi:9606">human</span>
CYP2D6 catalyses tamoxifen 4-hydroxylation in human liver
###end article-title 60
###begin article-title 61
Geometric isomers of substituted triphenylethylenes and antiestrogen action
###end article-title 61
###begin article-title 62
###xml 144 149 <span type="species:ncbi:9606">human</span>
Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxytamoxifen isomers in MCF-7 human breast cancer cells
###end article-title 62
###begin article-title 63
###xml 85 90 <span type="species:ncbi:9606">human</span>
Effect of 4-hydroxytamoxifen isomers on growth and ultrastructural aspects on normal human breast epithelial (HBE) cells in culture
###end article-title 63
###begin article-title 64
###xml 97 105 <span type="species:ncbi:9606">patients</span>
Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients
###end article-title 64
###begin article-title 65
###xml 68 71 68 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 77 82 77 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
###xml 106 111 <span type="species:ncbi:9606">human</span>
Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases
###end article-title 65
###begin article-title 66
###xml 22 28 22 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A </italic>
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
###end article-title 66
###begin article-title 67
The genetic determinants of CYP3A5 polymorphism
###end article-title 67
###begin article-title 68
###xml 33 38 <span type="species:ncbi:9606">human</span>
Genetic contribution to variable human CYP3A-mediated metabolism
###end article-title 68
###begin article-title 69
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D </italic>
###xml 130 137 130 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934----A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site
###end article-title 69
###begin article-title 70
###xml 74 82 74 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 44 50 <span type="species:ncbi:9606">humans</span>
Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype
###end article-title 70
###begin article-title 71
###xml 109 115 109 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2A1</italic>
###xml 117 124 117 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15</italic>
###xml 130 134 130 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT8</italic>
Catalog of 86 single-nucleotide polymorphisms (SNPs) in three uridine diphosphate glycosyltransferase genes: UGT2A1, UGT2B15, and UGT8
###end article-title 71
###begin article-title 72
###xml 43 45 43 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink">85</sup>
Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene
###end article-title 72
###begin article-title 73
###xml 91 99 <span type="species:ncbi:9606">patients</span>
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
###end article-title 73
###begin article-title 74
Phenol sulphotransferase SULT1A1 polymorphism: molecular diagnosis and allele frequencies in Caucasian and African populations
###end article-title 74
###begin article-title 75
###xml 133 141 <span type="species:ncbi:9606">patients</span>
Associtation of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients
###end article-title 75
###begin article-title 76
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes
###end article-title 76
###begin article-title 77
###xml 166 174 <span type="species:ncbi:9606">patients</span>
Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients
###end article-title 77
###begin article-title 78
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
###end article-title 78
###begin article-title 79
Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA
###end article-title 79
###begin article-title 80
###xml 80 87 80 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5 </italic>
Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes
###end article-title 80
###begin article-title 81
###xml 44 49 <span type="species:ncbi:9606">human</span>
Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism
###end article-title 81
###begin article-title 82
Cancer treatment and pharmacogenetics of cytochrome P450 enzymes
###end article-title 82
###begin article-title 83
###xml 80 88 <span type="species:ncbi:9606">patients</span>
Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy
###end article-title 83
###begin article-title 84
Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition
###end article-title 84
###begin article-title 85
###xml 70 75 <span type="species:ncbi:9606">women</span>
Medication use, tamoxifen (TAM), and TAM metabolite concentrations in women with breast cancer
###end article-title 85
###begin title 86
Figures and Tables
###end title 86
###begin p 87
###xml 60 67 60 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 203 211 203 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*1</italic>
###xml 322 330 322 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4</italic>
###xml 332 334 332 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 349 351 349 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*4</italic>
###xml 352 355 352 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*4 </italic>
###xml 359 361 359 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*1</italic>
###xml 362 364 362 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*1</italic>
###xml 366 368 366 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 383 385 383 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*4</italic>
###xml 386 389 386 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*4 </italic>
###xml 393 395 393 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*1</italic>
###xml 396 398 396 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*4</italic>
###xml 400 402 400 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 417 419 417 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*1</italic>
###xml 420 423 420 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*1 </italic>
###xml 427 429 427 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*1</italic>
###xml 430 432 430 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*4</italic>
###xml 137 145 <span type="species:ncbi:9606">patients</span>
###xml 179 187 <span type="species:ncbi:9606">patients</span>
###xml 257 265 <span type="species:ncbi:9606">patients</span>
###xml 298 306 <span type="species:ncbi:9606">patients</span>
Kaplan-Meier estimates for recurrence-free survival between CYP2D6 genotypes in oestrogen-receptor-positive postmenopausal breast cancer patients. The black solid line represents patients homozygous for CYP2D6*1, the grey solid line represents heterozygous patients, and the dotted line represents patients homozygous for CYP2D6*4. P = 0.05 between *4/*4 and *1/*1; P = 0.04 between *4/*4 and *1/*4; P = 0.16 between *1/*1 and *1/*4.
###end p 87
###begin p 88
###xml 77 85 77 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 168 178 168 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*1 </italic>
###xml 261 271 261 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1*2 </italic>
###xml 279 283 279 283 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 283 291 283 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 325 329 325 329 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 329 337 329 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SULT1A1 </italic>
###xml 40 48 <span type="species:ncbi:9606">patients</span>
###xml 140 148 <span type="species:ncbi:9606">patients</span>
###xml 217 225 <span type="species:ncbi:9606">patients</span>
Recurrence-free survival in ER-positive patients with different genotypes of SULT1A1 and tamoxifen randomisation. The solid line represents patients homozygous for the SULT1A1*1 allele, and the dotted line represents patients homozygous or heterozygous for the SULT1A1*2 allele. (a) SULT1A1 and 2 years of tamoxifen therapy; (b) SULT1A1 and 5 years of tamoxifen therapy.
###end p 88
###begin p 89
###xml 77 84 77 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5 </italic>
###xml 183 192 183 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*1 </italic>
###xml 259 268 259 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5*3 </italic>
###xml 276 280 276 280 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 280 287 280 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5 </italic>
###xml 321 325 321 325 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 325 332 325 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A5 </italic>
###xml 40 48 <span type="species:ncbi:9606">patients</span>
###xml 139 147 <span type="species:ncbi:9606">patients</span>
###xml 231 239 <span type="species:ncbi:9606">patients</span>
Recurrence-free survival in ER-positive patients with different genotypes of CYP3A5 and tamoxifen randomisation. The solid line represents patients homozygous or heterozygous for the CYP3A5*1 allele, and the dotted line represents patients homozygous for the CYP3A5*3 allele. (a) CYP3A5 and 2 years of tamoxifen therapy; (b) CYP3A5 and 5 years of tamoxifen therapy.
###end p 89
###begin p 90
###xml 77 84 77 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 167 176 167 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*1 </italic>
###xml 259 268 259 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6*4 </italic>
###xml 276 280 276 280 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 280 287 280 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 321 325 321 325 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 325 332 325 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP2D6 </italic>
###xml 40 48 <span type="species:ncbi:9606">patients</span>
###xml 139 147 <span type="species:ncbi:9606">patients</span>
###xml 215 223 <span type="species:ncbi:9606">patients</span>
Recurrence-free survival in ER-positive patients with different genotypes of CYP2D6 and tamoxifen randomisation. The solid line represents patients homozygous for the CYP2D6*1 allele, and the dotted line represents patients homozygous or heterozygous for the CYP2D6*4 allele. (a) CYP2D6 and 2 years of tamoxifen therapy; (b) CYP2D6 and 5 years of tamoxifen therapy.
###end p 90
###begin p 91
###xml 77 85 77 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 168 178 168 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15*1 </italic>
###xml 261 271 261 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15*2 </italic>
###xml 279 283 279 283 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 283 291 283 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 325 329 325 329 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 329 337 329 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UGT2B15 </italic>
###xml 40 48 <span type="species:ncbi:9606">patients</span>
###xml 140 148 <span type="species:ncbi:9606">patients</span>
###xml 217 225 <span type="species:ncbi:9606">patients</span>
Recurrence-free survival in ER-positive patients with different genotypes of UGT2B15 and tamoxifen randomisation. The solid line represents patients homozygous for the UGT2B15*1 allele, and the dotted line represents patients homozygous or heterozygous for the UGT2B15*2 allele. (a) UGT2B15 and 2 years of tamoxifen therapy; (b) UGT2B15 and 5 years of tamoxifen therapy.
###end p 91
###begin p 92
###xml 10 12 8 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
Use of chi2 test to compare genotype and tumour characteristics in ER-positive patients with breast cancer
###end p 92
###begin p 93
###xml 21 23 21 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 52 53 52 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 101 109 <span type="species:ncbi:9606">patients</span>
Results are shown as n (%). ER, oestrogen receptor. aInformation on tumour size was missing for five patients.
###end p 93
###begin p 94
Hazard ratio (HR) between genotypes and randomisation calculated with the Cox proportional-hazard model
###end p 94
###begin p 95
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Cases with less than 2 years of follow-up time were excluded. For each randomisation, patients with the proposed 'low-risk' alleles were used as reference. CI, confidence interval.
###end p 95

